Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-12-08 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于向深圳市禾沐基因生物技术有限责任公司增资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding a capital increase and related party transaction involving Shenzhen Huada Gene Co., Ltd. It details the board resolution approving the capital injection, the increase in registered capital, and the completion of the related registration with the market supervision authority. The document is short (1460 characters) and focuses on the update of a financing transaction rather than a full financial report or detailed financial data. It does not contain financial statements or comprehensive financial analysis. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-12-08 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二二年第五次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2022 fifth extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It details the legality and compliance of the meeting's call, attendance, voting procedures, and results with relevant laws and company rules. The document focuses on the validation and certification of the shareholder meeting process and voting outcomes, which corresponds to the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is lengthy (8119 characters) and contains detailed voting results and legal opinions on the meeting's conduct, not just an announcement or a brief notice. Therefore, it is classified as DVA with high confidence.
2022-12-06 Chinese
2022年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 fifth extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, attendance, voting results on multiple proposals, and legal opinions confirming the validity of the meeting and votes. The content focuses on the official voting results of shareholder decisions on stock incentive plans and employee shareholding plans. There is no indication that this is a full report like an annual or interim report, nor is it a presentation or management discussion. The document is not a notice of a report publication but the actual voting results announcement. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5358 characters) and detailed voting data support this classification with high confidence.
2022-12-06 Chinese
关于2022年限制性股票激励计划内幕信息知情人及首次授予激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading and stock transactions related to a 2022 restricted stock incentive plan by Shenzhen BGI Genomics Co., Ltd. It details the investigation procedures, findings, and compliance with regulations concerning insider information and stock trading by insiders and incentive recipients. The document is an announcement of the results of an internal investigation and compliance check, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is a regulatory disclosure related to insider trading compliance and stock incentive plans, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories like Director's Dealing (DIRS) which typically reports individual insider trades rather than a compliance report. The document length is short (1919 characters), and it is a formal announcement of a compliance self-check report, not a full report itself or a notice of voting or capital changes.
2022-12-06 Chinese
第二期员工持股计划第一次持有人会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the first meeting of holders of the company's second employee stock ownership plan. It details the meeting attendance, voting results, and decisions regarding the establishment and authorization of a management committee for the employee stock plan. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content focuses on governance and management of the employee stock plan, which is related to management information but specifically about the employee stock plan's internal governance and decisions. This fits best under Board/Management Information (MANG) as it announces management committee formation and related governance decisions. The document length is short (2095 characters) and is a meeting resolution announcement, not a full report or financial statement.
2022-12-06 Chinese
第二期员工持股计划
Capital/Financing Update Classification · 95% confidence The document is a detailed description of Shenzhen BGI Genomics Co., Ltd.'s second employee stock ownership plan. It includes information about the plan's purpose, principles, participants, funding sources, stock sources, scale, purchase price, lock-up periods, performance assessments, management structure, and risk disclosures. The document is lengthy (15,000 characters) and contains substantive content about the employee stock ownership plan, including financial and operational details. It is not a brief announcement or a certification letter. It is not an annual or quarterly financial report, nor an earnings release or a call transcript. It is a comprehensive disclosure about an employee stock ownership plan, which is a form of capital/financing update related to company fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-12-06 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.